Noema Pharma, a clinical-stage biotech company, has appointed Volker Knappertz, M.D., as Executive Vice President of Research & Development. With over 25 years in drug development, Dr. Knappertz's expertise is expected to be pivotal as Noema enters a transformative year with multiple Phase 2 study readouts.

A University of Minnesota study found that hydroxychloroquine did not prevent COVID-19 infection in high-risk healthcare workers, with 5.9% of the hydroxychloroquine group and 7.9% of the placebo group developing the virus.

Stanford University has commenced a Phase 1 clinical trial to assess the safety and efficacy of CAR-T cell therapy targeting the B7-H3 antigen in pediatric patients with solid tumors.

Oxford University is conducting a clinical trial using 'Petrushka,' an AI tool, to personalize antidepressant treatment for individuals with depression.

Cambridge University Hospitals (CUH) has played a crucial role in early-phase trials, contributing to advancements in gynecological cancer care and innovation.

Professor Collen Masimirembwa leads a multinational study across Nigeria, Kenya, Zimbabwe, and South Africa to explore how genes affect medication response.

Bret Rutherford, formerly of Columbia University, was found to have committed research misconduct by falsely reporting subject eligibility in late-life depression studies.

Eli Lilly and Purdue University have announced an expanded collaboration worth up to $250 million to advance pharmaceutical research and development across multiple therapeutic areas.

Eli Lilly and Purdue University have announced a landmark collaboration worth up to $250 million over eight years, potentially becoming the largest industry-academic agreement of its kind in the United States.

Taipei Medical University and MSD Taiwan have signed a groundbreaking Memorandum of Understanding to collaborate across six key areas, marking the first large-scale alliance between a global pharmaceutical company and a medical university in Taiwan.

Researchers at Osaka University have developed a novel immune cell therapy specifically targeting acute myeloid leukemia (AML), potentially offering hope for patients who experience cancer recurrence after conventional treatments.

Khyber Medical University (KMU) has finalized arrangements for conducting clinical trials of a new indigenously developed drug for leishmaniasis, marking a significant step forward in medical research and treatment options for the disease.

University Hospitals is the only health system in Northeast Ohio offering donanemab (Kisunla™), an FDA-approved treatment for Alzheimer's disease.

Researchers at Bond University are trialing stem cell therapies in pigs to treat blindness, specifically targeting age-related macular degeneration and retinitis pigmentosa.

Panjab University has filed Indian and international patents for an eco-friendly nanomicelle platform that enables targeted delivery of sensitive bioactives including peptides, cannabinoids, and proteins.

University Hospitals is the first health system in Northeast Ohio to offer donanemab (Kisunla™), an FDA-approved treatment for Alzheimer's disease.

University Hospitals receives $7 million from PCORI to study endovascular thrombectomy (EVT) in stroke patients presenting after 24 hours of last known well.

A $1.5 million NIH grant supports the development of a patient-centered decision aid for early Deep Brain Stimulation (DBS) consideration in Parkinson's disease.

Brooks Rehabilitation partners with UCF, JU, and UF to launch the Eric Sorensen Motor Speech Program (ESMSP) for adults with motor speech disorders.

UT Health San Antonio has been awarded $12 million to develop methocinnamox (MCAM) for opioid use disorder.